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Objective. To demonstrate the feasibility and acceptability of introducing postpartum voluntary counselling and testing (PPVCT)
and the provision of post-exposure nevirapine prophylaxis (PEP) to HIV-exposed infants whose mothers did not receive any
antiretroviral prophylaxis to prevent mother-to-child transmission (PMTCT) in a large, tertiary hospital in the South African
setting.
Design. Observational, interventional study.
Setting. The programme was implemented at Chris Hani Baragwanath Hospital (tertiary referral centre) in Soweto, South Africa,
following a study that established the efficacy of a postpartum regimen of PEP in PMTCT. 
Participants. From January 2003 to December 2004, 7 500 women who delivered at Chris Hani Baragwanath Hospital without a
documented HIV-1 result were identified in the postnatal wards. PPVCT was offered to all eligible participants. 
Intervention. On-site HIV rapid tests were performed on all women who agreed to testing. For those women testing HIV-1
positive, a single dose of nevirapine syrup was offered to their infants as PEP within 72 hours after delivery. Infant feeding
counselling, assistance with follow-up care and support programmes were also offered.
Main outcome. From January 2003 to December 2004, 34 776 deliveries occurred at Chris Hani Baragwanath Hospital. Of these,
7 500 (21.5%) had no documented HIV status. After delivery 5 751 (76.7%) women were offered VCT, and of these 3 794 (66%)
accepted testing. Of these women, 1 294 (34%) tested HIV positive and 1 243 (96%) women accepted the administration of
single-dose nevirapine to their infants.
Conclusions. The uptake of PPVCT is comparable to that seen in established antenatal VCT despite the numerous challenges PPVCT
presents. This suggests that PPVCT is both an acceptable and a feasible option in a busy, resource-limited setting and remains an
important strategy in PMTCT in untreated individuals.
In 2003, the World Health Organization (WHO)  estimated that
approximately 40 million people worldwide are HIV infected.1 At
present more than 5 million people are thought to be HIV
infected in South Africa alone.1 The HIV epidemic has had a
profound impact on the health of people living in Soweto, an
urban black township of approximately 2 million people
situated on the outskirts of Johannesburg, South Africa.
Prevalence rates of HIV-1 in pregnant women have increased
from 15.5% in 1996 to over 30% in 2004 in our region (national
HIV and syphilis antenatal seroprevalence). Perinatal HIV
transmission rates vary from 37% (untreated women who
breast-feed) to less than 7% for women identified in pregnancy
who access antiretroviral therapy and do not breast-feed. 
At Chris Hani Baragwanath Hospital (CHBH), voluntary
counselling and testing (VCT) services have been available to
pregnant women who attend antenatal services at the hospital
since 1988. In 1999, on-site rapid testing was introduced with
the option to be tested and counselled on the same day. In
addition, models of VCT have been developed within the
midwifery units in Soweto. These units received training and
support from the Perinatal HIV Research Unit (PHRU) for the
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implementation of programmes to prevent mother-to-child
transmission (PMTCT) thus ensuring that all pregnant women
who attended antenatal care in Soweto were eligible for rapid
on-site VCT and nevirapine (NVP) prophylaxis if they tested
positive. Annually the current PMTCT programme reaches out to
approximately 28 000 pregnant women in Soweto.2 Most of
these women will receive individual pre-test counselling (over
89%) with a high acceptance of testing (over 90%). 
Unfortunately, these figures do not reflect either the availability
or the uptake of antenatal VCT throughout South Africa.
Overall, it is believed that the proportion of pregnant women
who have access to HIV counselling, testing and nevirapine
(NVP) is less than 15%.3 It is widely accepted that the
identification of HIV-positive women is the cornerstone of the
prevention strategy. Although the PMTCT programme is
growing rapidly, there are still vast numbers of women who are
not identified antenatally as being HIV infected and therefore
do not have the opportunity of receiving the benefits of post-
exposure prophylaxis (PEP). These women include those who
have not booked, those who refused testing when offered
initially, those who were tested but never returned for their
results, those who had forgotten to take their NVP, and those
who may be in denial of their status. NVP PEP to the infant has
been shown to be efficacious in a study performed in South
Africa4 and was implemented soon after the results of this
study became available.
Evidence supporting the role of PEP antiretroviral therapy (ART)
in reducing MTCT of HIV in infants whose mothers did not
access therapy during pregnancy or labour has been
demonstrated in a prospective study in two studies in Africa
that investigated post-labour and delivery exposure prophylaxis
in newborns.4, 5 With the advent of the new-generation simple
and rapid HIV tests women were able to be tested safely and
accurately soon after delivery. These tests are sensitive and
reliable, do not require expensive laboratory equipment, do not
require refrigeration, provide a result within 15 - 30 minutes
and can be read by trained non-laboratory staff. The WHO has
evaluated many of the tests and has issued recommendations
as to which of them are acceptable. This is particularly
important in our setting, where a policy of early discharge after
delivery creates a huge challenge to delivering a comprehensive
postpartum voluntary counselling and testing (PPVCT) service.
Testers, nurse counsellors and lay counsellors were trained to
conduct the PPVCT service. All women who had delivered at
CHBH and had no documented HIV result were identified after
delivery in the postnatal wards. Test information and pretest
counselling was provided on an individual level as soon as the
patient had sufficiently recovered from her delivery.
Counselling was done either by the nurse councillors or the lay
counsellors. No standardised time period after delivery was
used, but each patient was assessed individually before pretest
counselling was commenced. Owing to staff shortages, PPVCT
services were only offered during routine working hours
(Monday to Friday 07h30 - 16h00). The authors acknowledge
that this system does allow for some women and children to be
missed, and plans have been made to offer services on
weekends as well. Women who agreed to pretest counselling
were counselled in the procedure rooms, adjacent to the wards.
Phlebotomy was performed by a registered phlebotomist and
samples were tested a short distance away from the wards in a
room designated for PPVCT testing. 
The testing was performed by counsellors who had been trained
to test using rapid HIV tests. The blood samples were initially
tested with Determine HIV-1/2 test kits (Abbott Laboratories,
Abbott Park, IL). Women who tested negative at this test were
considered to be uninfected with HIV. If the test result was
positive, a second confirmatory test was performed using Uni-
Gold (Trinity Biotech, Wicklow, Ireland). The Determine HIV-1/2
assay has been found to have a sensitivity of 97.9 - 100% with
a specificity of 100%. The Uni-Gold HIV test has been found to
have a sensitivity of 99.8% and a specificity of 100%. For
quality assurance purposes 20% of specimens were selected
randomly to be sent to the main laboratory for ELISA testing for
antibodies to HIV-1/2. 
Where possible, test results were given on the same day by the
same person who had done the original pretest counselling.
Women who tested positive (two different rapid tests on the
same specimen) received post-test counselling on being HIV
infected and on safer infant feeding and were offered the
option of NVP being given to the baby once the risks and
benefits had been explained. No child was given NVP without
the informed consent of the mother. 
Nurse counsellors or lay counsellors were also available to do
the additional post-test counselling where required and
facilitate the referral of HIV-positive women into a support
group within their community. Women testing HIV negative
(one rapid negative) received a short post-test counselling
session and a pamphlet on HIV prevention. Women whose
results were discordant or difficult to interpret were sent for a
routine HIV-1 enzyme-linked immunosorbent assay (ELISA).
Infants whose mothers had accepted administration of NVP
were given a single dose of NVP syrup (2 mg/kg) by a registered
nursing sister employed by the PPVCT service. As with all drugs,
the provision of NVP requires an adequate drug distribution
and monitoring system, and a strict drug log book was kept and
monitored by the resident pharmacist.
Table I indicates the number of women who were offered and
received PPVCT from January 2003 to December 2004,
including the number who delivered at CHBH; the number with
no HIV status documented; the number who were offered
PPVCT; the number who accepted testing and tested positive;
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As shown in Table I, between January 2003 and December 2004,
34 776 deliveries occurred at CHBH. Of these, 7 500 (21.5%) had
no documented HIV status. PPVCT was offered to 5 751 women,
with 3 794 of these patients accepting testing (66% uptake).
Women who were considered to be ineligible for PPVCT were
those who had a stillbirth or miscarriage; were too ill to be
counselled and give informed consent; or spoke a foreign
language if no interpreter was available. Occasionally a woman
was not in the ward when the counsellor did her rounds and
was therefore not offered VCT.
Of the women who accepted testing, 1 294 (34%) tested HIV
positive. These results are slightly higher than those in the local
antenatal clinics.2 Of the women with a positive result, 1 243
(96%) accepted the administration of single-dose NVP to their
infants.
An uptake of PPVCT of 66% is comparable to that seen in
established antenatal VCT despite the numerous challenges
PPVCT presents.2 Although formal questionnaires were not
administered to participants, the general response to the
counsellors was favourable, as suggested by the relatively high
uptake of PPVCT. Furthermore, the very high acceptance of NVP
(96%) is extremely encouraging.
COSTS
The study that established the efficacy of NVP PEP in PMTCT
was funded by Secure the Future. The PPVCT and PMTCT service
was funded by USAID and utilised very few existing resources
within the hospital. EDTA tubes, needles and syringes were
supplied by the hospital. Office space and counselling space
was allocated for the PPVCT staff. Confidentiality became an
issue at times as the procedure rooms were not always vacant,
but the staff remained flexible and either returned later or used
other quiet, private areas. As no pre-existing HIV
testing/counselling services were available in the postnatal
wards, the service was utilised heavily by obstetric and
paediatric doctors alike. The staff employed to run the day-to-
day operations consisted of two lay counsellors, one trained
nursing sister and one tester. 
The total cost of providing the postpartum voluntary
counselling and testing service for 2003 was R307 224 (US$
51 204 – estimated exchange rate US$1 = R6). During the
period January - December 2003 a total of 2 202 women with
unknown HIV status accepted PPVCT. The cost per woman who
accepted – including testing and administering NVP to those
babies whose mothers were positive and accepted it – averaged
R139 (US$23) per woman. 
These results suggest that PPVCT is an acceptable, feasible and
affordable option and has a role to play even in areas with
successful antenatal VCT programmes and where antenatal
clinic attendance is very high. It remains to be seen how many
mothers will bring their children back for testing at 1 year of
age, and an analysis of HIV results at 1 year of age still needs to
be done. The purpose of this paper is to illustrate that PPVCT
and NVP PEP for infants is a practical, realistic option even in
busy, resource-limited settings.
Despite heavy workloads, limited resources (staff and
equipment) and reluctance of patients to test for HIV, PPVCT
appears to be both a feasible and acceptable option and allows
us to utilise the window of opportunity which exists within the
first 72 hours after delivery. At this point the cost-effectiveness
of the postpartum NVP regimen, as well as its ease of
implementation, makes it a particularly desirable tool in the
struggle to break the cycle of perinatal transmission. It is clear
that PPVCT with the provision of PEP and infant feeding
counselling remains an important strategy in PMTCT in
untreated individuals.
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2003 2004
Total No. of deliveries 15 847 18 929
Status documented 11 829 7 100
Status not documented 4 025 3 475
Offered VCT 3 095 2 656
Accepted testing 2 202 1 592
Percentage uptake 71 60
HIV-1 positive 685 609
Accepted NVP 647 596
Percentage uptake NVP 94 98
TABLE I. PPVCT OUTCOMES FOR 2003 AND 2004
CONCLUSION
This study was funded by a grant from the Bristol-Myers
Squibb Secure the Future Programme (RES 057-02) and by
additional funding from the United States Agency for
International Development (USAID: 674-0320-G-00-5053).
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